Market Overview

GW Pharma Soars 35% on Initiation from Morgan Stanley, Bullish Comments by Jim Cramer

Share:

On Tuesday, Morgan Stanley initiated coverage on shares of GW Pharmaceuticals (NASDAQ: GWPH) with an Overweight rating and $103 price target, sending the shares $15 higher to $61.

Analyst David Friedman believes the company's cannabis platform “has strong potential, with the epilepsy program driving valuation.” Epidiolex, a purified CBD extract, accounts for 90 percent of the analysts peak revenue.

“While small and still anecdotal, there is a consistently strong and building set of data (case cohort and controlled) which highlight the positive impact of CBD on refractory epilepsy pts,” said Friedman.

The analyst sees most of “Sativex growth to come from the US mkt over time, with Ph 3 trials in advanced cancer pain and MS spasticity providing the next steps.”

At 9:55 a.m., Jim Cramer made some bullish comments on the stock and is the one cannabis stock he actually recommends to those looking for a piece of the medical marijuana space. His comments sent the stock spiking again.

Latest Ratings for GWPH

DateFirmActionFromTo
Aug 2020Raymond JamesInitiates Coverage OnMarket Perform
Aug 2020HC Wainwright & Co.MaintainsBuy
Aug 2020NeedhamMaintainsBuy

View More Analyst Ratings for GWPH
View the Latest Analyst Ratings

 

Related Articles (GWPH)

View Comments and Join the Discussion!

Posted-In: David Friedman Jim Cramer Morgan StanleyAnalyst Color Initiation Analyst Ratings Movers Media

Latest Ratings

StockFirmActionPT
TSLAJP MorganMaintains125.0
INTCTruist SecuritiesMaintains64.0
FBTruist SecuritiesMaintains320.0
GSCitigroupMaintains370.0
AAPLCowen & Co.Maintains153.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com